Halozyme Therapeutics Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | $0 | $151.0M | $147.7M |
| FY2021 | $787.3M | $197.0M | $118.7M |
| FY2022 | $1.49B | $169.8M | $234.2M |
| FY2023 | $1.50B | $83.8M | $118.4M |
| FY2024 | $1.51B | $363.8M | $115.9M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | $0 | $151.0M | $147.7M |
| FY2021 | $787.3M | $197.0M | $118.7M |
| FY2022 | $1.49B | $169.8M | $234.2M |
| FY2023 | $1.50B | $83.8M | $118.4M |
| FY2024 | $1.51B | $363.8M | $115.9M |